Based on these results, the company intends to proceed with a confirmatory in-vitro study with additional dilution levels to fully explore the capabilities of the QR-435 compound. The new study will also be conducted by Retroscreen Virology Ltd., and should the new study confirm the previous results, animal model studies will be considered as a next step in the development process.

Richard Rosenbloom, MD, Ph.D., Executive Vice President and Chief Operations Officer of Quigley Pharma, stated, "Previous in-vitro and in-vivo studies have suggested that QR-435 has broad anti-viral properties for applications such as Influenza A&B , SARS, and Herpes Simplex 1. Therefore, in view of these current findings, it is clear that this interesting formulation has therapeutic potential and we intend to embark on the FDA regulatory path for approval."

Given the broad anti-viral properties of QR-435, the company intends to pursue further development as a prescription medication, and thus will reconsider the ongoing testing of its compound QR-334, a derivative compound, which was intended as an over-the-counter medication. QR-334 is currently being evaluated in clinical trials to relieve Sialorrhea, excess secretions of the salivary glands.

Retroscreen Virology Limited is an independent research virology company affiliated with the University of London. Professor John S. Oxford, the firm's senior scientist, is Professor of Virology at St. Bartholomew's and The Royal London School of Medicine and Dentistry at the University of London. Dr. Oxford is the co-author of two standard texts on influenza and virology and has published more than 250 scientific papers throughout the world. Retroscreen specializes in developing anti-viral compounds and vaccines, and has worked with many pharmaceutical companies to assist them in developing products that now help to fight viral disease worldwide. Additional information is available on the company's website at www.retroscreen.com.

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the Cold-Eeze® family of patented zinc gluconate glycine (ZIGG^TM) lozenges and sugar free tablets. Cold-Eeze is the only (ZIGG^TM) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will grant an IND or take any other action to allow the aforementioned products to be studied or marketed. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.